{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:35:10Z","timestamp":1788813310622,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1124\/jpet.119.263392","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:45:23Z","timestamp":1587516323000},"page":"74-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy"],"prefix":"10.1016","volume":"374","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3286-4319","authenticated-orcid":false,"given":"Anna Thors\u00f8","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Sonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Vietz","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Asser","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.263392_bib1","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1152\/ajpendo.00121.2014","article-title":"A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats","volume":"307","author":"Andreassen","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/jpet.119.263392_bib2","doi-asserted-by":"crossref","first-page":"e92042","DOI":"10.1371\/journal.pone.0092042","article-title":"Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias","volume":"9","author":"Andreassen","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.263392_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1056-8719(00)00074-5","article-title":"Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor","volume":"42","author":"Armour","year":"1999","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/jpet.119.263392_bib4","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1210\/jc.2006-2003","article-title":"Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study","volume":"92","author":"Aronne","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.119.263392_bib5","doi-asserted-by":"crossref","first-page":"e0180547","DOI":"10.1371\/journal.pone.0180547","article-title":"Differential effects of Calca-derived peptides in male mice with diet-induced obesity","volume":"12","author":"Bartelt","year":"2017","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.263392_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0026-895X(24)08983-1","article-title":"Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product","volume":"56","author":"Christopoulos","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.119.263392_bib7","doi-asserted-by":"crossref","first-page":"R856","DOI":"10.1152\/ajpregu.00179.2018","article-title":"Rodent models of leptin receptor deficiency are less sensitive to amylin","volume":"315","author":"Duffy","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/jpet.119.263392_bib8","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1345\/aph.1M210","article-title":"The role of pramlintide for weight loss","volume":"44","author":"Dunican","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1124\/jpet.119.263392_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejphar.2014.05.016","article-title":"Oral salmon calcitonin enhances insulin action and glucose metabolism in diet-induced obese streptozotocin-diabetic rats","volume":"737","author":"Feigh","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.263392_bib10","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1210\/en.2012-2172","article-title":"Amylin acts in the central nervous system to increase sympathetic nerve activity","volume":"154","author":"Fernandes-Santos","year":"2013","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.119.263392_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08977190410001728033","article-title":"Calcitonin","volume":"22","author":"Findlay","year":"2004","journal-title":"Growth Factors"},{"key":"10.1124\/jpet.119.263392_bib12","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00514.2015","article-title":"KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight","volume":"310","author":"Gydesen","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/jpet.119.263392_bib13","doi-asserted-by":"crossref","first-page":"E598","DOI":"10.1152\/ajpendo.00419.2016","article-title":"Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog","volume":"313","author":"Gydesen","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/jpet.119.263392_bib14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"Suppl 2","key":"10.1124\/jpet.119.263392_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/head.13077","article-title":"Amylin","volume":"57","author":"Hay","year":"2017","journal-title":"Headache"},{"key":"10.1124\/jpet.119.263392_bib16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.119.263392_bib17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1146\/annurev-pharmtox-010715-103120","article-title":"Receptor activity-modifying proteins (RAMPs): new insights and roles","volume":"56","author":"Hay","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.119.263392_bib18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1042\/BST20150237","article-title":"Receptor activity-modifying proteins; multifunctional G protein-coupled receptor accessory proteins","volume":"44","author":"Hay","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"10.1124\/jpet.119.263392_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2016.07.019","article-title":"A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D","volume":"91","author":"Henriksen","year":"2016","journal-title":"Bone"},{"key":"10.1124\/jpet.119.263392_bib20","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.4158\/EP13477.OR","article-title":"Effects of pramlintide in patients with type 2 diabetes mellitus: an analysis using daily insulin dose tertiles","volume":"20","author":"Herrmann","year":"2014","journal-title":"Endocr Pract"},{"key":"10.1124\/jpet.119.263392_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejphar.2015.05.051","article-title":"KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration","volume":"762","author":"Hjuler","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.263392_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/jpet.117.241281","article-title":"The dual amylin- and calcitonin-receptor agonist KBP-042 works as adjunct to metformin on fasting hyperglycemia and HbA1c in a rat model of type 2 diabetes","volume":"362","author":"Hjuler","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.263392_bib23","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/oby.21563","article-title":"The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity","volume":"24","author":"Hjuler","year":"2016","journal-title":"Obesity (Silver Spring)"},{"key":"10.1124\/jpet.119.263392_bib24","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.119.263392_bib25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1515\/JPEM.2004.17.7.931","article-title":"Calcitonin: physiological actions and clinical applications","volume":"17","author":"Inzerillo","year":"2004","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1124\/jpet.119.263392_bib26","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1476-5381.2012.01911.x","article-title":"The use of animal models in diabetes research","volume":"166","author":"King","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.263392_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1124\/jpet.119.257576","article-title":"The dual amylin and calcitonin receptor agonist KBP-088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy","volume":"370","author":"Larsen","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.263392_bib28","doi-asserted-by":"crossref","unstructured":"Lutz TA (2012) Effects of amylin on eating and adiposity, Handb Exp Pharmacol 209, pp 231\u2013250, \u00a9Springer-Verlag.","DOI":"10.1007\/978-3-642-24716-3_10"},{"key":"10.1124\/jpet.119.263392_bib29","first-page":"A389","article-title":"Sustained reduction in food intake and body weight in high-fat-fed rats during 28-day amylin infusion (Abstract)","volume":"52","author":"Mack","year":"2003","journal-title":"Diabetes"},{"key":"10.1124\/jpet.119.263392_bib30","doi-asserted-by":"crossref","first-page":"R1855","DOI":"10.1152\/ajpregu.00297.2007","article-title":"Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight","volume":"293","author":"Mack","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/jpet.119.263392_bib31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1463-1326.2011.01465.x","article-title":"Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide","volume":"13","author":"Mack","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.119.263392_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.mce.2012.12.008","article-title":"Amylin stimulates fatty acid esterification in 3T3-L1 adipocytes","volume":"366","author":"Miegueu","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"10.1124\/jpet.119.263392_bib33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc10-0518","article-title":"Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans","volume":"34","author":"Moon","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.119.263392_bib34","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1210\/endo.140.6.6930","article-title":"An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3","volume":"140","author":"Muff","year":"1999","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.119.263392_bib35","doi-asserted-by":"crossref","first-page":"17001","DOI":"10.1038\/s41598-018-35369-5","article-title":"Endogenous calcitonin regulates lipid and glucose metabolism in diet-induced obesity mice","volume":"8","author":"Nakamura","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.119.263392_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.biomaterials.2015.09.011","article-title":"Enhanced thermogenic program by non-viral delivery of combinatory browning genes to treat diet-induced obesity in mice","volume":"73","author":"Park","year":"2015","journal-title":"Biomaterials"},{"key":"10.1124\/jpet.119.263392_bib37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2337\/diabetes.47.3.358","article-title":"Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat","volume":"47","author":"Pick","year":"1998","journal-title":"Diabetes"},{"key":"10.1124\/jpet.119.263392_bib38","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med"},{"key":"10.1124\/jpet.119.263392_bib39","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.2337\/dc07-0589","article-title":"Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin","volume":"30","author":"Riddle","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.119.263392_bib40","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1210\/en.2006-0393","article-title":"Antiobesity effects of the \u03b2-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression","volume":"147","author":"Roth","year":"2006","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.119.263392_bib41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/DDDT.S3225","article-title":"Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes","volume":"2","author":"Ryan","year":"2008","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/jpet.119.263392_bib42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.bjp.0703328","article-title":"Effects of peroxisome proliferator-activated receptor-\u03b1 and -\u03b3 agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats","volume":"130","author":"Shibata","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.263392_bib43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1463-1326.2010.01337.x","article-title":"The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis","volume":"13","author":"Singh-Franco","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.119.263392_bib44","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/dc08-0029","article-title":"Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity","volume":"31","author":"Smith","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.119.263392_bib45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/BF00252763","article-title":"Effects of calcium and calcitonin on circulating levels of glucagon and glucose in diabetes mellitus","volume":"20","author":"Starke","year":"1981","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.119.263392_bib46","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1359\/JBMR.040715","article-title":"Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover","volume":"19","author":"Tank\u00f3","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1124\/jpet.119.263392_bib47","doi-asserted-by":"crossref","first-page":"E1730","DOI":"10.1152\/ajpendo.00572.2007","article-title":"Dynamics of insulin sensitivity, -cell function, and -cell mass during the development of diabetes in fa\/fa rats","volume":"293","author":"Topp","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/jpet.119.263392_bib48","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/0145721711403011","article-title":"Primer on pramlintide, an amylin analog","volume":"37","author":"Traina","year":"2011","journal-title":"Diabetes Educ"},{"key":"10.1124\/jpet.119.263392_bib49","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1210\/en.2010-0590","article-title":"Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats","volume":"151","author":"Trevaskis","year":"2010","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.119.263392_bib50","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control","volume":"7","author":"Weyer","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1124\/jpet.119.263392_bib51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.physbeh.2010.04.012","article-title":"Central amylin acts as an adiposity signal to control body weight and energy expenditure","volume":"101","author":"Wielinga","year":"2010","journal-title":"Physiol Behav"},{"key":"10.1124\/jpet.119.263392_bib52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1054-3589(05)52003-9","article-title":"Receptor pharmacology","volume":"52","author":"Young","year":"2005","journal-title":"Adv Pharmacol"},{"key":"10.1124\/jpet.119.263392_bib53","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/14656566.2011.581663","article-title":"Pramlintide and the treatment of diabetes: a review of the data since its introduction","volume":"12","author":"Younk","year":"2011","journal-title":"Expert Opin Pharmacother"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.263392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:54:46Z","timestamp":1739973286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524257906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0022356524257906"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.263392","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.263392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}